Tat cell-penetrating peptide conjugated to lipids successfully fused extracellular vesicles with liposomes, creating hybrid drug delivery vehicles more efficiently than existing methods.
True membrane fusionFour independent analytical methods confirmed that Tat-PEG-lipids induced genuine membrane fusion between EVs and liposomes, not mere aggregation
What the researchers found
Tat-PEG-lipids successfully induced membrane fusion between extracellular vesicles and DPPC/cholesterol liposomes. Dynamic light scattering showed increased apparent size. FRET, confocal microscopy, and TEM confirmed true membrane fusion (not aggregation). Shorter lipid anchors (C9 and C12) with 5 kDa PEG chains produced the cleanest fusion results.
Why it matters
Hybrid EV-liposome particles could combine the best of both worlds: EVs' natural targeting ability and biocompatibility with liposomes' drug-loading capacity and manufacturability. A simple peptide-based fusion method could make these advanced drug carriers practical to produce.
The numbers in context
Not specified — proof-of-concept demonstrating CPP-mediated fusion efficiency.
How the study worked
In vitro study. EVs isolated from HEK293T cell culture medium. Liposomes composed of DPPC and cholesterol (1:1 molar ratio). Tat-PEG-lipids synthesized with three lipid anchor lengths (C9, C12, C14) and 5 kDa PEG. Fusion analyzed by dynamic light scattering, fluorescence resonance energy transfer (FRET), confocal laser scanning microscopy, and transmission electron microscopy (TEM).
Who was studied
In vitro EV-liposome fusion and hybrid characterization
What this study cannot tell us
Proof-of-concept in vitro study only. No drug loading or release experiments performed. No cellular uptake or in vivo testing of the hybrid particles. The Tat peptide may trigger immune responses in vivo. Scalability and reproducibility of the fusion process not assessed.
How to read the evidence
Rated preliminary: in vitro proof-of-concept demonstrating a novel fusion method. No drug loading, cellular uptake, or in vivo data. Multiple analytical methods strengthen the fusion conclusion.
When this study was published
Published in 2024. Builds on the group's previous work with Tat peptide-mediated cell-liposome fusion.
The bigger picture
This work advances the field of bio-hybrid drug delivery by showing that cell-penetrating peptides can serve as molecular matchmakers between natural and artificial carriers. If scaled, this could enable next-generation therapeutics that exploit the body's own communication system.
Questions still open
- Can these EV-liposome hybrids be loaded with therapeutic cargo and show improved drug delivery compared to either vehicle alone?
- How do the hybrid particles perform in vivo — do they retain the targeting properties of the parent EVs?
- Could other cell-penetrating peptides produce even more efficient or controllable fusion?
Common questions
What are EV-liposome hybrids and why do they matter?
How does the Tat peptide help create these hybrids?
Read the original research
Extracellular vesicle-liposome hybrids via membrane fusion using cell-penetrating peptide-conjugated lipids.
Regenerative therapy, 26, 533-540
Citation
Sato, Yuya; Zhang, Weixu; Baba, Teruhiko; Chung, Ung-Il; Teramura, Yuji. (2024). Extracellular vesicle-liposome hybrids via membrane fusion using cell-penetrating peptide-conjugated lipids.. Regenerative therapy, 26, 533-540. https://doi.org/10.1016/j.reth.2024.07.006